TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2596812

Group type: EXPERIMENTAL
Intervention: Iopromide 320
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 39
Study: 824553

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic exercise therapy with bencyclane (treatment group, n = 45)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (control group, n = 46)
Number of subjects: 91
Study: 12094921

Group type: EXPERIMENTAL
Intervention: Aminophylline 5mg kg(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NaCl 0.9% (Control Group)
Number of subjects: 100
Study: 29789415

Group type: EXPERIMENTAL
Intervention: Elastic tubes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Elastic bands
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Conventional bodybuilding
Number of subjects: 34
Study: 26963737

Group type: EXPERIMENTAL
Intervention: CT+NFT
Number of subjects: 92

Group type: COMPARATOR
Intervention: CT
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 25006684

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22611116

Group type: EXPERIMENTAL
Intervention: M1: Taken 'OFF' CPAP with the view to stay 'OFF'
Number of subjects: 177

Group type: COMPARATOR
Intervention: M2: Cycled on and off CPAP with incremental time 'OFF'
Number of subjects: 177

Group type: COMPARATOR
Intervention: M3: Cycled on and off CPAP with 2 mm nasal cannula support during 'OFF' periods
Number of subjects: 177
Study: 20375719

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study: 18474025

Group type: EXPERIMENTAL
Intervention: Intermittent high dosage oral ibandronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily low dose ibandronate
Number of subjects: 0
Study: 15513977

Group type: EXPERIMENTAL
Intervention: Anastrozole ('Arimidex') alone or in combination with tamoxifen
Number of subjects: 285

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound scanning (TVUS)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Endometrial thickness assessment
Number of subjects: 285
Study: 11996196

Group type: EXPERIMENTAL
Intervention: bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 164
Study: 10215737

Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7630617

Group type: EXPERIMENTAL
Intervention: Basic programme (BP) of standard autogenic relaxation exercises
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Advanced programme (AP) with special exercises in ocular relaxation and imagination of aqueous humour drainage
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Twenty-four-hour IOP profiles and water drinking test
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Medication reduction
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 23
Study: 2203289

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 318981

Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: pyrantel pamoate
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: bephenium hydroxynaphthoate
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: thiabendazole
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study: 31317460

Group type: EXPERIMENTAL
Intervention: Oxygen administration through a nasopharyngeal airway and standard nasal cannula
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no apneic oxygenation)
Number of subjects: 135
Study: 28067693

Group type: EXPERIMENTAL
Intervention: Intraoperative S-ketamine bolus 0.5 mg/kg and infusion 0.25 mg·kg·h
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intraoperative S-ketamine
Number of subjects: 150
Study: 24251378

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 144

Group type: COMPARATOR
Intervention: Orlistat medication therapy plus low-fat diet
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 144
Study: 23176716

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Prodentis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21680990

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d plus glyburide
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d plus glyburide
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d plus thiazolidinedione
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d plus thiazolidinedione
Number of subjects: 547

Group type: COMPARATOR
Intervention: placebo add-on
Number of subjects: 547
Study: 19395295

Group type: EXPERIMENTAL
Intervention: Compression procedure guided by mean arterial pressure (experimental)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Compression procedure using 15 cubic centimeters of air (standard)
Number of subjects: 351
Study: 16686723

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg once daily)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 513
Study: 14990524

Group type: EXPERIMENTAL
Intervention: Testimony method intervention (n=66)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (n=71)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 206
Study: 11271790

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily) for 10 weeks
Number of subjects: 5
Study: 9493923

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8199416

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) providing 41 +/- 2 kcal, 0.30 +/- 0.02 g N kg‐1.day‐1, and 40 mg pyridoxine for 14 days.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Taurine supplementation at a dosage of 8.6 mg.kg‐1.day‐1.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control subjects (not specified in detail).
Number of subjects: 51
Study: 3593812

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29886765

Group type: EXPERIMENTAL
Intervention: Strengthened quitter self-identity
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (neutral)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Social support present
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Social support absent
Number of subjects: 339
Study: 27406028

Group type: EXPERIMENTAL
Intervention: FenuSMART™ (fenugreek extract) 1000 mg/day for 90 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 24356886

Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion at 12 pmol · kg(‐1) · min(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lo-Xen infusion at 4 pmol · kg(‐1) · min(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion for 90 or 300 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion for 30 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion
Number of subjects: 10
Study: 23614845

Group type: EXPERIMENTAL
Intervention: Mobil‐O‐Graph
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spacelabs 90207
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both monitors
Number of subjects: 24
Study: 20942615

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Lysteda)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 18697894

Group type: EXPERIMENTAL
Intervention: Exercise therapy intervention
Number of subjects: 0
Study: 15855325

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day) for 12 weeks
Number of subjects: 2
Study: 12543751

Group type: EXPERIMENTAL
Intervention: Genetic mapping using a positional candidate gene approach on DNA samples from affected individuals.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clinical examination including A-scan and B-scan ultrasonography and electrophysiological testing.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Screening of candidate genes within the NNO1 locus.
Number of subjects: 9
Study: 10551920

Group type: EXPERIMENTAL
Intervention: dopexamine (1 microg/kg/min)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo (0.9% NaCl)
Number of subjects: 34
Study: 8733744

Group type: EXPERIMENTAL
Intervention: Visual naming task using standardized line drawings
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Letter fluency task
Number of subjects: 7
Study: 1833813

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMP) administered at progressive doses for 8 days (maximum dosage 75 mg) in the evening at 6 p.m.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (glucose solution infusion) administered morning and evening.
Number of subjects: 68
Study: 6801213

Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Phenytoin (300 mg/day)
Number of subjects: 88
Study: 31994431

Group type: EXPERIMENTAL
Intervention: Descending-ascending method of TPD testing
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Descending with randomization method of TPD testing
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Two-point estimation (TPE) method
Number of subjects: 35
Study: 30711528

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg bid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study: 28624175

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 156
Study: 26256280

Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve replacement (TF‐TAVR)
Number of subjects: 1521
Study: 24637966

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 84
Study: 22021897

Group type: EXPERIMENTAL
Intervention: Both DAS28 and MMP‐3‐driven therapy (T group)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Routine care (R group)
Number of subjects: 243

Group type: COMPARATOR
Intervention: MMP‐3‐driven therapy (M group)
Number of subjects: 243
Study: 19346511

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with 50 microg nicotine/puff
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with 100 microg nicotine/puff
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cigarette
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI)
Number of subjects: 10
Study: 16854595

Group type: EXPERIMENTAL
Intervention: Masked primes during ongoing pointing movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visible masks
Number of subjects: 0
Study: 15351759

Group type: EXPERIMENTAL
Intervention: Bienestar Health Program
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1419
Study: 11224630

Group type: EXPERIMENTAL
Intervention: Delayed primary closure (E/DPC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 51
Study: 11229224

Group type: EXPERIMENTAL
Intervention: Aspirin (at lower doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 7811344

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAME); 2 g daily in 250 ml 0.15 M NaCl for 15 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (alcoholic patients without treatment)
Number of subjects: 40
Study: 2898932

Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride
Number of subjects: 25

Group type: COMPARATOR
Intervention: Timolol maleate
Number of subjects: 25
Study: 9511622

Group type: EXPERIMENTAL
Intervention: Myprodol (Ibuprofen, Paracetamol and Codeine phosphate)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ponstan (Mefenamic acid)
Number of subjects: 52
Study: 332607

Group type: EXPERIMENTAL
Intervention: Antacids containing Mg (OH)2, Al (OH)3 and CaCO3, administered after meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30648197

Group type: COMPARATOR
Intervention: Conventional group (CGCL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Guided surgery but conventional loading group (GSCL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Guided surgery and immediate loading group (GSIL)
Number of subjects: 104
Study: 28720140

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy informed by stakeholders
Number of subjects: 400

Group type: COMPARATOR
Intervention: Basic implementation strategy (intervention as usual)
Number of subjects: 400
Study: 25888344

Group type: EXPERIMENTAL
Intervention: Audio Relaxation Technique (ART)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Music Intervention (MI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nature Video Application with Music (NVAM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nature Video Application without Music (NVA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 105
Study: 24377635

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Poor academic achievement
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Ever-smoker
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Having a smoking friend
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Perception that smoking prohibition in school was strictly enforced
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Had never seen friends smoking in a school compound
Number of subjects: 1736
Study: 21445573

Group type: EXPERIMENTAL
Intervention: Axillary dissection surgery (G1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 60
Study: 19305020

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and Simvastatin 40 mg (coadministered)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17365949

Group type: EXPERIMENTAL
Intervention: Broad-based coping skills condition (including autogenic training, imagery, and self‐talk)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Broad-based coping skills condition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 15125120

Group type: EXPERIMENTAL
Intervention: Cementless, hemispherical, modular, titanium acetabular cup
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cemented, all‐polyethylene cup
Number of subjects: 115
Study: 11704900

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavioural therapy (general)
Number of subjects: 120
Study: 9491231

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg once daily for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 12
Study: 7840417

Group type: EXPERIMENTAL
Intervention: Ketamine racemate (1 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.5 mg/kg)
Number of subjects: 16
Study: 2974675

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 100 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29723928

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Dehydro-aripiprazole
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 473

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 473

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 473

Group type: COMPARATOR
Intervention: Agomelatine
Number of subjects: 473
Study: 28662281

Group type: EXPERIMENTAL
Intervention: Monthly provider funnel plot feedback reports and semiannual face‐to‐face coaching sessions for 12 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 25970080

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation in addition to comprehensive medical treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comprehensive medical treatment alone (Control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation
Number of subjects: 51
Study: 24165815

Group type: EXPERIMENTAL
Intervention: Modified protocol (flattening and enclosing serrated polyps in a paper envelope before placing in formalin)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Modified protocol
Number of subjects: 264

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 264
Study: 21245070

Group type: EXPERIMENTAL
Intervention: Direct Optical Entry (DOE)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Open Laparoscopy (OL)
Number of subjects: 168
Study: 19551674

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily for 12 weeks
Number of subjects: 70
Study: 16713661

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 15214959

Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampicin (400 mg/day plus 600 mg/day for 30 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Doxycycline plus rifampicin (200 mg/day plus 600 mg/day for 45 days)
Number of subjects: 29
Study: 10737828

Group type: EXPERIMENTAL
Intervention: Multiple-family group psychoeducation treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63
Study: 8889681

Group type: EXPERIMENTAL
Intervention: 1.75% THC cigarette
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.55% THC cigarette
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 6
Study: 1643800

Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Porcine Insulin (PI)
Number of subjects: 10
Study: 6332903

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 46

Group type: COMPARATOR
Intervention: TENS at 100 Hz
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TENS at 8 Hz
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30486801

Group type: EXPERIMENTAL
Intervention: Four additional healthier options (compared to two healthier and two less healthy options)
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Four additional less healthy options (compared to two healthier and two less healthy options)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Two healthier and two less healthy options
Number of subjects: 1509
Study: 28417196

Group type: EXPERIMENTAL
Intervention: Sustaining rod
Number of subjects: 122

Group type: COMPARATOR
Intervention: Rod-less protocol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High BMI (>26)
Number of subjects: 122
Study: 25758874

Group type: EXPERIMENTAL
Intervention: Gabapentin (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa-c (110 mg)
Number of subjects: 0
Study: 23838349

Group type: EXPERIMENTAL
Intervention: Clofarabine 20 mg/m² on days 1 to 5 for up to 4 courses
Number of subjects: 406

Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC) 20 mg twice daily for 10 days every 6 weeks for up to 4 courses
Number of subjects: 406
Study: 20492056

Group type: EXPERIMENTAL
Intervention: Heat application (20-minute sessions every other day for four weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine medication (control group)
Number of subjects: 46
Study: 18782532

Group type: EXPERIMENTAL
Intervention: Jinlong Capsule (TACE therapy plus Jinlong Capsule)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (TACE therapy alone)
Number of subjects: 48
Study: 16052202

Group type: EXPERIMENTAL
Intervention: Counterweight programme intervention
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Counterweight programme intervention (completers)
Number of subjects: 1549
Study: 12665497

Group type: EXPERIMENTAL
Intervention: Chronic right atrial stretch due to ASD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Follow-up after ASD closure (8.3±5.6 months)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 13
Study: 10825854

Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Plus Whitening Fluoride dentifrice (test dentifrice)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control dentifrice (non-tooth whitening dentifrice)
Number of subjects: 79
Study: 7490386

Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prompted Voiding (PV)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (FIT and PV)
Number of subjects: 76